SEC Comment Letter for Entera Bio Ltd. (ENTX, ENTXW) (CIK 0001638097) (ENTX) — Jun 12, 2018
Entera Bio Ltd. (ENTX, ENTXW) (CIK 0001638097)
Date: June 12, 2018 · CIK: 0001638097 · Accession: 0000000000-18-017987
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-221472
Letter
June 11, 2018 Phillip Schwartz Chief Executive Officer Entera Bio Ltd. Kiryat Hadassah Minrav Building - Fifth Floor Jerusalem 9112002 Israel Re:Entera Bio Ltd. Amendment No. 4 to Registration Statement on Form F-1 Filed May 17, 2018 File No. 333-221472 Dear Dr. Schwartz: We have reviewed your amended registration statement and have the following comment. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this comment, we may have additional comments. Amendment No. 4 to Form F-1 filed May 17, 2018 Use of Proceeds, page 58 1.We note your revised disclosure that you will need to raise additional capital for the Phase 2b/3 trial of EB612 and for the Phase 2a trial for EB613. Please further revise to describe how far in the clinical development, and specifically these trials, you expect to reach with the proceeds from this offering. You may contact Franklin Wyman at 202-551-3660 or Mark Brunhofer at 202-551-3638 if you have questions regarding comments on the financial statements and related
FirstName LastNamePhillip Schwartz Comapany NameEntera Bio Ltd. June 11, 2018 Page 2 FirstName LastName Phillip Schwartz Entera Bio Ltd. June 11, 2018 Page 2 matters. Please contact Ada D. Sarmento at 202-551-3798 or Mary Beth Breslin at 202-551- 3625 with any other questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Sophia Hudson, Esq.
Show Raw Text
June 11, 2018
Phillip Schwartz
Chief Executive Officer
Entera Bio Ltd.
Kiryat Hadassah
Minrav Building - Fifth Floor
Jerusalem 9112002
Israel
Re:Entera Bio Ltd.
Amendment No. 4 to Registration Statement on Form F-1
Filed May 17, 2018
File No. 333-221472
Dear Dr. Schwartz:
We have reviewed your amended registration statement and have the following
comment.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comment applies to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to this comment, we may have additional comments.
Amendment No. 4 to Form F-1 filed May 17, 2018
Use of Proceeds, page 58
1.We note your revised disclosure that you will need to raise additional capital for the Phase
2b/3 trial of EB612 and for the Phase 2a trial for EB613. Please further revise to describe
how far in the clinical development, and specifically these trials, you expect to reach with
the proceeds from this offering.
You may contact Franklin Wyman at 202-551-3660 or Mark Brunhofer at 202-551-3638
if you have questions regarding comments on the financial statements and related
FirstName LastNamePhillip Schwartz
Comapany NameEntera Bio Ltd.
June 11, 2018 Page 2
FirstName LastName
Phillip Schwartz
Entera Bio Ltd.
June 11, 2018
Page 2
matters. Please contact Ada D. Sarmento at 202-551-3798 or Mary Beth Breslin at 202-551-
3625 with any other questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Sophia Hudson, Esq.